Regulacje i polityka gospodarcza · 16/12/2019

National Cancer Institute to Grant Exclusive Patent License for CAR Therapy for AML, CLL, and Other Leukemias to T-CURX GmbH

The National Cancer Institute is considering granting an exclusive patent license to T-CURX GmbH, a German company, to develop and use a chimeric antigen receptor (CAR) for treating acute myeloid leukemia, chronic lymphocytic leukemia, and other forms of B- and T-cell leukemias and lymphomas.